Secondhand vape plumes could form lung-damaging radicals
Peer-Reviewed Publication
Updates every hour. Last Updated: 10-Jun-2026 02:16 ET (10-Jun-2026 06:16 GMT/UTC)
Electronic cigarettes — or vapes — can release puffs of vapor in aromatic clouds. The health risks of breathing in this secondhand or passive vapor aren’t fully understood. So, researchers reporting in ACS’ Environmental Science & Technology conducted a preliminary study on lingering vape plumes in indoor environments. They found that aged vapor contained fine particles with several metals and highly reactive compounds, which together produce radicals that might damage lung tissue if inhaled.
The Ottawa Medical Artificial Intelligence Research Institute (OMARI) will empower responsible medical AI advances to strengthen healthcare systems and improve patient care; OMARI will raise awareness about the power of commercialization and next-gen innovation.
Long-term research and new policy frameworks needed / Practical barriers must be overcome / Six concrete areas for action identified
The electrostatic potential of particular matter is a promising resource for energy harvesting. In a recent breakthrough, a team of researchers from Chung-Ang University has developed a next-generation Tesla turbine-inspired structure for contactless electricity generation. The proposed technology utilizes electrostatic charges and the viscous force of compressed air to achieve a peak output of 800 V and 2.5 A at frequency of 325 Hz.
Scientists from the Research Center for Materials Nanoarchitectonics (MANA) developed a liquid-repellent particle coating that allows pico- and nanoliter liquid droplets to be handled like dry powder, enabling precise control of ultra-small liquid volumes in microfluidics applications.
This review provides a comprehensive analysis of Growth Differentiation Factor 15 (GDF15) in prostate cancer (PCa), examining its complex influence on tumor metabolism, chemoresistance, and bone metastasis. GDF15 is identified as a critical driver of PCa progression and cancer cachexia, offering diagnostic potential as a biomarker, especially when combined with PSA. The review highlights promising ongoing clinical trials involving monoclonal antibodies (e.g., AV-380, NGM120, Visugromab) that target GDF15 signaling, marking it as a significant therapeutic opportunity for novel PCa therapie